Cannabis Pharmaceuticals Market By Product Type (Cannabinoid-Based Drugs, Synthetic Cannabinoids, Herbal Cannabis Products), By Application (Pain Management, Neurological Disorders, Oncology, Sleep Disorders), By Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies, Specialty Clinics), and By Region; Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Cannabis Pharmaceuticals Market was valued at USD 1.9 billion in 2023 and will surpass USD 30.2 billion by 2030; growing at a CAGR of 49.1% during 2024 - 2030.

The cannabis pharmaceuticals market has gained significant momentum in recent years, driven by an increasing number of countries and states legalizing medical cannabis and the growing recognition of its therapeutic potential. Cannabis-based medicines, derived primarily from cannabinoids like CBD (cannabidiol) and THC (tetrahydrocannabinol), are increasingly being used for a variety of medical conditions ranging from chronic pain to neurological disorders. With the expanding research into the benefits of cannabis and its derivatives, coupled with regulatory advancements and growing patient acceptance, the market is poised for strong growth. As more patients turn to cannabis for treatment, pharmaceutical companies are enhancing their focus on developing targeted treatments that can meet diverse medical needs.

Cannabinoid-Based Drugs Segment Is Largest Owing to Growing Demand for CBD and THC Products

Cannabinoid-based drugs, particularly those containing CBD and THC, are the largest segment in the cannabis pharmaceuticals market. These drugs are increasingly recognized for their efficacy in treating chronic pain, neurological conditions, and certain forms of cancer. CBD, known for its non-psychoactive properties, has been widely studied for its potential in managing anxiety, epilepsy, and inflammation. THC, the psychoactive component, has found success in managing pain, nausea, and appetite loss, especially in cancer and AIDS patients. The growing clinical evidence supporting the benefits of these cannabinoids in treating various conditions has driven the demand for these drugs. As a result, pharmaceutical companies are investing heavily in cannabinoid-based drug research and development.

One of the key drivers for the large-scale adoption of cannabinoid-based drugs is the increasing approval of CBD and THC-based medications by regulatory bodies like the U.S. FDA. Epidiolex, a CBD-based drug, was one of the first to be approved for the treatment of seizures in patients with rare forms of epilepsy. This approval has paved the way for more cannabinoid-based drugs to enter the market, solidifying their role as the dominant treatment option within the cannabis pharmaceutical sector.

Neurological Disorders Application Is Fastest Growing Due to Increasing Recognition of Cannabis Benefits

The application of cannabis pharmaceuticals in neurological disorders is the fastest-growing segment, largely driven by the growing body of research highlighting the therapeutic benefits of cannabinoids in managing conditions like epilepsy, multiple sclerosis (MS), Parkinson’s disease, and Alzheimer’s. Among these, CBD has shown significant promise, particularly in managing seizure disorders like epilepsy. It is also being explored for its potential neuroprotective properties, making it a viable treatment option for neurodegenerative diseases.

As more clinical trials demonstrate the efficacy of cannabis-based treatments in reducing symptoms associated with neurological disorders, demand for these therapies continues to rise. This surge in interest is also supported by growing patient advocacy and the endorsement of cannabis by various medical communities, leading to an expansion of the cannabis pharmaceuticals market in the neurological application segment. Additionally, the acceptance of cannabis-based therapies for children with intractable epilepsy further accelerates growth in this area.

Retail Pharmacies Distribution Channel Is Largest Due to Wide Accessibility and Consumer Trust

Retail pharmacies remain the largest distribution channel for cannabis pharmaceuticals due to their widespread accessibility and the consumer trust they have built over the years. Patients typically prefer obtaining their medications from pharmacies as they are more regulated and trusted than other channels. Retail pharmacies also offer a range of cannabis pharmaceutical products, including prescription-based CBD and THC-based drugs, making them a one-stop solution for those seeking treatment.

In many regions, retail pharmacies have established strong relationships with healthcare providers, ensuring seamless patient access to cannabis-based medications. As more countries and regions legalize cannabis for medical use, retail pharmacies are expanding their offerings, and their role in the cannabis pharmaceutical distribution chain is expected to continue growing. Their established infrastructure for handling patient prescriptions further reinforces their dominance in the distribution of these products.

North America Region Is Largest Due to Favorable Regulatory Environment and High Demand

North America remains the largest region in the cannabis pharmaceuticals market, primarily driven by the United States and Canada. Both countries have seen significant regulatory advancements that have facilitated the growth of the cannabis pharmaceuticals industry. In the U.S., the 2018 Farm Bill legalized hemp-derived CBD products, while several states have approved medical marijuana programs, fostering a more extensive market for cannabis-based treatments. Additionally, the U.S. FDA's approval of cannabis-derived medications such as Epidiolex has spurred greater confidence in cannabis-based treatments, accelerating the growth of the market.

In Canada, the legalization of both medical and recreational cannabis in 2018 has positioned the country as a global leader in the cannabis space. The Canadian government's progressive stance on cannabis has provided a strong foundation for the development of cannabis-based pharmaceuticals, creating a well-regulated market that attracts both local and international companies. As the demand for cannabis-based pharmaceuticals increases, North America is expected to continue dominating the global market in terms of both revenue and innovation.

Leading Companies and Competitive Landscape

The cannabis pharmaceuticals market is highly competitive, with both large pharmaceutical companies and specialized cannabis firms vying for market share. Some of the key players include GW Pharmaceuticals (now part of Jazz Pharmaceuticals), which has pioneered the development of CBD-based drugs such as Epidiolex. Other notable companies include Tilray, Canopy Growth Corporation, and Aurora Cannabis, all of which are investing in R&D to develop innovative cannabis-based treatments. These companies are focused on expanding their product portfolios, navigating complex regulatory landscapes, and securing partnerships with healthcare providers to drive growth.

The competitive landscape is also shaped by the increasing number of biotech firms focused on cannabinoid-based drug development. While traditional pharmaceutical giants are leading the market, smaller companies with expertise in cannabinoid science are emerging as significant players. This growing competition is fostering innovation and driving advancements in the development of new cannabis pharmaceuticals. The market's future will likely be characterized by strategic mergers and acquisitions, partnerships, and collaborations aimed at enhancing product offerings and expanding market reach

Recent Developments:

• GW Pharmaceuticals (Jazz Pharmaceuticals) received FDA approval for Epidiolex to treat additional forms of epilepsy, marking a significant step in expanding its portfolio of cannabis-based drugs.
• Tilray announced a strategic acquisition of Aphria to create a global cannabis powerhouse, with a focus on expanding their medicinal cannabis product line.
• Canopy Growth launched new CBD-infused wellness products, including oils and tinctures, targeting the growing consumer demand for non-psychoactive cannabis alternatives.
• Aurora Cannabis obtained EU-GMP certification for its cannabis products, positioning itself as a leader in the European medicinal cannabis market.
• Zynerba Pharmaceuticals reported successful clinical trial results for its CBD-based treatments for rare pediatric epilepsy disorders, further boosting its product pipeline and market credibility

List of Leading Companies:

• XXXXX

Report Scope: